Eiken Chemical Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations
Updated 2026/08/01Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥29 | -48.2% |
| 2025 | ¥56 | +7.7% |
| 2024 | ¥52 | 0.0% |
| 2023 | ¥52 | -5.5% |
| 2022 | ¥55 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥43,271M | ¥40,052M | ¥40,539M | ¥41,899M |
| Gross Profit | ¥20,506M | ¥16,723M | ¥16,512M | ¥16,175M |
| Operating Income | ¥7,457M | ¥3,378M | ¥3,000M | ¥2,920M |
| Pretax Income | ¥7,608M | ¥3,520M | ¥3,008M | ¥4,863M |
| Net Income | ¥5,736M | ¥2,634M | ¥2,228M | ¥3,708M |
| EPS | ¥153.86 | ¥71.10 | ¥64.27 | ¥112.08 |
| Operating Margin | 17.23% | 8.43% | 7.40% | 6.97% |
| Balance Sheet | ||||
| Total Assets | ¥66,275M | ¥61,651M | ¥62,372M | ¥62,657M |
| Total Equity | ¥49,534M | ¥45,970M | ¥43,596M | ¥44,033M |
| Total Liabilities | ¥16,741M | ¥15,681M | ¥18,776M | ¥18,624M |
| Cash | ¥18,317M | ¥16,308M | ¥9,873M | ¥10,943M |
| Interest-bearing Debt | ¥4,309M | ¥4,335M | ¥4,466M | ¥7,291M |
| Equity Ratio | 74.74% | 74.56% | 69.90% | 70.28% |
| D/E Ratio | 0.09 | 0.09 | 0.10 | 0.17 |
| Cash Flow | ||||
| Operating CF | ¥7,575M | ¥3,806M | ¥6,033M | ¥4,045M |
| Investing CF | -¥316M | -¥2,216M | -¥4,499M | -¥3,423M |
| Financing CF | -¥2,095M | -¥6,694M | -¥4,857M | -¥322M |
| Free CF | ¥4,297M | ¥1,716M | ¥655M | -¥1,923M |
| Efficiency | ||||
| ROE | 11.58% | 5.73% | 5.11% | 8.42% |
| ROA | 8.65% | 4.27% | 3.57% | 5.92% |
Latest IR Information
-
2027 Fiscal Year First Quarter Financial Results Supplementary Explanation Materials
Eiken Chemical's financial results for the first quarter of fiscal year 2027 show net sales of approximately 10,728 million yen, a 5.2% increase YoY. Despite a 21.3% decrease YoY in operating profit to approximately 640 million yen, the company continues...
Read more -
First Quarter Financial Results for Fiscal Year Ending March 2027 【Eiken Chemical】 Revenue of 1.07 billion yen, Net profit of 445 million yen
Eiken Chemical achieved revenue of 1.07 billion yen and net profit of 445 million yen in the first quarter of fiscal year ending March 2027. Revenue increased YoY, and net profit remained solid.
Read more -
【Eiken Chemical】Introduction of Shareholder Benefits and Promotion of Electronic Voting｜July 2026
Eiken Chemical will introduce a shareholder benefit program at the Board of Directors meeting on July 30, 2026, offering QUO Card Pay to long-term shareholders. Additionally, the company will promote electronic voting to enhance convenience and reduce environmental impact.
Read more -
【Eiken Chemical】Share Buyback Completion｜July 2026
Eiken Chemical announced that on July 22, 2026, they disposed of 27,217 treasury shares, totaling 72,560,522 yen.
Read more -
【Sk-chemicals】Share Buyback and Incentive System｜July 2026
Sk-chemicals plans to dispose of 27,217 shares of treasury stock on July 22, 2026, raising approximately 72,560,522 yen. The disposal is part of an incentive system for officers and employees, with a disposal price of 2,666 yen per share. Details...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,100
Rating Score: 3.00 (Based on - analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Eiken Chemical Co., Ltd. engages in the manufacture and sale of clinical diagnostics in Japan. It offers microbiological reagents for diagnosis of microorganism infection, such as mediums, antimicrobial susceptibility, and rapid test reagents; urinalysis test strips for occult blood, protein, and glucose; and fecal immunochemical tests reagents for screening of colorectal cancer. The company also provides immunological and serological reagents to detect and monitor infectious disease, rheumatism, inflammation, atrophic gastritis, and prostate specific antigens; and clinical chemistry tests reagents to measure and analyze biological components in blood serum and urine. In addition, it sells reagents and devices of microbiological test for food poisoning bacteria and environmental inspection; and offers molecular test (LAMP) using nucleic acid amplification method, as well as provides various types of automated analyzers. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was incorporated in 1939 and is headquartered in Tokyo, Japan.
